Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma

BACKGROUND: As angiogenesis is an essential step in tumor growth and metastasis, the tyrosine kinase inhibitor (TKI) apatinib has become a revolutionary anticancer therapy across various malignancies. However, its efficiency and safety in Merkel cell carcinoma (MCC) are uncertain. CASE PRESENTATION:...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yiyi, Song, Xin, Jia, Renbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966513/
https://www.ncbi.nlm.nih.gov/pubmed/33747940
http://dx.doi.org/10.3389/fonc.2021.625360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966513/
https://www.ncbi.nlm.nih.gov/pubmed/33747940
http://dx.doi.org/10.3389/fonc.2021.625360

Ejemplares similares